Mutational analysis of mitochondrial DNA in Brugada syndrome

详细信息    查看全文

• 作者：Laura Stocchi^a ; ¹ ; Emanuela Polidori^b ; ¹ ; Lucia Potenza^b ; ¹ ; ^{lucia.potenza@uniurb.it" class="auth_mail" title="E-mail the corresponding author} ; Marco Bruno Luigi Rocchi^b ; Cinzia Calcabrini^b ; Paolo Busacca^c ; Maria Capalbo^d ; Domenico Potenza^e ; Francesca Amati^a ; Ruggiero Mango^f ; Francesco Romeo^f ; ^g ; Giuseppe Novelli^a ; ^h ; ⁱ ; Vilberto Stocchi^b
• 关键词：Brugada syndrome ; mtDNA ; mtSNPs ; Sequence analysis ; Risk stratification
• 刊名：Cardiovascular Pathology
• 出版年：2016
• 出版时间：January-February 2016
• 年：2016
• 卷：25
• 期：1
• 页码：47-54
• 全文大小：889 K

文摘

Brugada syndrome (BrS) is a primary electrical disease associated with an increased risk of sudden cardiac death due to ventricular fibrillation. This pathology has nuclear heterogeneous genetic origins, and at present, molecular diagnostic tests on nuclear DNA cover only 30% of BrS patients. The aim of this study was to assess the possible involvement of mitochondrial (mt) DNA variants in BrS since their etiological role in several cardiomyopathies has already been described.

Methods and Results

The whole mt genome of BrS patients was sequenced and analyzed. A specific mtDNA mutation responsible for BrS can be excluded, but BrS patient d-loop was found to be more polymorphic than that of control cases (P= 0.003). Moreover, there appears to be an association between patients with the highest number of variants (n> 20) and four mt Single Nucleotide Polymorphism (SNPs) (T4216C, A11251G, C15452A, T16126C) and the most severe BrS phenotype (P= 0.002).

Conclusions

The high substitution rate found in BrS patient mtDNA is unlikely to be the primary cause of the disease, but it could represent an important cofactor in the manifestation of the BrS phenotype.

Evidence suggesting that a specific mtDNA allelic combination and a high number of mtDNA SNPs may be associated with more severe cases of BrS represents the starting point for further cohort studies aiming to test whether this mt genetic condition could be a genetic modulator of the BrS clinical phenotype.